Education
About Us
Working with TipRanks
Follow Us
Immuron (IMRN)
:IMRN
IMRN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.50 - $2.87
Previous CloseN/A
Volume5.19K
Average Volume (3M)50.88K
Market Cap
$12.82M
Enterprise ValueN/A
Total Cash (Recent Filing)$7.74M
Total Debt (Recent Filing)$135.62K
Price to Earnings (P/E)―
Beta-0.24
Next Earnings
Mar 04, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.30
Shares Outstanding6,705,499
10 Day Avg. Volume44,469
30 Day Avg. Volume50,878
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$1.50Price Target Upside-16.67% Downside
Rating ConsensusHold
Number of Analyst Covering0
Immuron News
IMRN FAQ
What was Immuron’s price range in the past 12 months?
Immuron lowest stock price was $1.50 and its highest was $2.87 in the past 12 months.
What is Immuron’s market cap?
Immuron’s market cap is $12.82M.
When is Immuron’s upcoming earnings report date?
Immuron’s upcoming earnings report date is Mar 04, 2026 which is in 166 days.
How were Immuron’s earnings last quarter?
Immuron released its earnings results on Aug 28, 2025. The company reported -$0.3 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.3.
Is Immuron overvalued?
According to Wall Street analysts Immuron’s price is currently Overvalued.
Does Immuron pay dividends?
Immuron does not currently pay dividends.
What is Immuron’s EPS estimate?
Immuron’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Immuron have?
Immuron has 6,705,499 shares outstanding.
What happened to Immuron’s price movement after its last earnings report?
Immuron reported an EPS of -$0.3 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 0.549%.
Which hedge fund is a major shareholder of Immuron?
Currently, no hedge funds are holding shares in IMRN
Company Description
Immuron
Immuron Limited (IMRN) is a biopharmaceutical company focused on the research, development, and commercialization of oral immunotherapy products for the treatment of gut-mediated diseases. The company's core products are based on its proprietary technology platform that utilizes colostrum-derived polyclonal antibodies. Immuron's primary product, Travelan, is designed to reduce the risk of travelers' diarrhea and is marketed in several countries. The company is also involved in developing treatments for non-alcoholic steatohepatitis (NASH) and Clostridium difficile infections.
Technical Analysis
Relmada Therapeutics
―
AlphaTON Capital
―
Bioxcel Therapeutics
―
Citius Pharmaceuticals
―
Hookipa Pharma
―
Ownership Overview
―
Insiders
―
Mutual Funds
0.02% Other Institutional Investors
99.98% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---